Tempus AI CEO Highlights Blood Tests for Early Cancer Recurrence Detection, Citing Record Growth
Eric Lefkofsky, founder and CEO of Tempus AI, stated on the MTS podcast that blood draws can detect cancer recurrence six to twelve months earlier than traditional scans. This capability is central to Tempus AI's strategy, which leverages a vast dataset of 600 petabytes, growing by 50 petabytes quarterly, derived from over 8,000 hospital data connections across more than half of the United States. These connections integrate real-time clinical data with molecular data from Tempus's own sequencing labs to provide oncologists with treatment insights. The company reported a record quarter in September 2026, with total revenue increasing by approximately 23%, cancer testing volumes up 32%, and its data and AI business growing by 33%. Lefkofsky emphasized that general-purpose AI models are insufficient for oncology due to the specialized nature of genomic and clinical data and the high accuracy demands of clinical use.